One-stop product solution for in vitro ADME studies of AOCs drugs

                                                                                                     
Revolutionary Therapeutics: Antibody-Oligonucleotide Conjugates (AOCs) – The Future of Precision Medicine

In the rapidly evolving world of biopharmaceuticals, Antibody-Oligonucleotide Conjugates (AOCs) are emerging as a groundbreaking class of drugs, combining the precise targeting power of antibodies with the gene-regulating potential of oligonucleotides. These innovative therapies are designed to deliver oligonucleotides—short strands of DNA or RNA—directly to specific cells or tissues, ensuring unparalleled precision in treatment. This dual-action approach opens new possibilities for tackling challenging conditions such as cancer, genetic disorders, and immune system diseases.

Why AOCs Are Game Changers

AOCs are composed of three critical elements: an antibody, an oligonucleotide, and a linker. This unique combination requires careful consideration during development, especially in pharmacokinetic studies. Unlike traditional small molecule drugs, oligonucleotides possess unique characteristics—high molecular weight, strong polarity, and a higher negative charge—which make them fundamentally different. In early drug development, it is crucial to conduct plasma/serum stability studies to ensure the oligonucleotide component remains intact, as they are susceptible to degradation by nucleases. The stability and release of the oligonucleotide in the targeted cells are key to the success of AOCs.

Furthermore, the method of coupling the oligonucleotide to the antibody directly impacts how effectively the drug is released within the cell, particularly in lysosomes. This critical factor means AOCs require specialized bioanalytical methods for pharmacokinetic studies, making the precision of their design and analysis indispensable to their efficacy.

                                                                                     
                                                                                                          By Oleksandr Koniev - Own work, CC BY-SA 4.0

IPHASE: Your Partner in AOC Innovation

At IPHASE, we are supporting the next wave of AOC drug development with cutting-edge in vitro bio-reagents. With a comprehensive range of bio-reagents, we help pharmaceutical researchers achieve breakthrough results in AOC drug screening and development. Our extensive portfolio of ADME research reagents, designed specifically for small molecules, macromolecules, and conjugated drugs, provides the critical tools needed to ensure success in early drug development.

With years of expertise and innovation, IPHASE offers a complete suite of in vitro research reagents for AOC drugs and beyond. Whether you are developing AOCs, small molecules, or any other drug class, IPHASE is committed to providing the solutions you need to drive your research forward and bring the next generation of therapies to life.

Discover the Future of Drug Development with IPHASE—because precision medicine deserves precision tools.